The development of an effective AIDS vaccine has been challenging because of viral
genetic diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs). We …

INTRODUCTION A major goal of HIV-1 vaccine development is to identify immunogens
capable of inducing protective titers of broadly neutralizing antibodies (bNAbs) against …

INTRODUCTION It is widely believed that the development of an effective neutralizing
antibody–based HIV-1 vaccine will require consistent activation of multiple germline …

INTRODUCTION HIV newly infects 1.8 million people each year, making development of an
HIV vaccine a global health priority. Nearly all licensed vaccines protect by inducing …

A major roadblock to the development of an effective vaccine against the human
immunodeficiency virus (HIV-1) is the lack of an immunogen that elicits broadly protective …

Germline-targeting immunogens hold promise for initiating the induction of broadly
neutralizing antibodies (bnAbs) to HIV and other pathogens. However, antibody-antigen …

A major goal of HIV-1 vaccine research is the design of immunogens capable of inducing
broadly neutralizing antibodies (bnAbs) that bind to the viral envelope glycoprotein (Env) …

HIV–1 neutralizing antibodies: How full is the bottle? | Nature Medicine Skip to main content
Thank you for visiting nature.com. You are using a browser version with limited support for …

Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1–infected
individuals, but the virologic basis of their neutralization remains poorly understood. We …

Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …